Strong Buy · 85/100Aug 4, 11:21 PM EDT
Amgen Raises 2026 Revenue and EPS Outlook Ahead of CFO Change
AMGNAMGN:CA
Amgen (AMGN) raised its 2026 guidance, now expecting revenue of $38.2B-$39.4B and non-GAAP EPS of $22.30-$23.50, as Q2 revenue surpassed $10B (up 10% YoY) with 22 products achieving double-digit growth. The updated outlook signals strong operational momentum,…
- ▹Raised 2026 guidance with strong revenue growth and diversified portfolio
- ▹Large-cap biotech with commercialized products and manufacturing scale
Watchlist · 78/100Aug 4, 9:20 PM EDT
Gilead Raises HIV Growth Forecast to 9-10% and Sets 2026 Base Business Sales at $29.8B-$30.1B
GILDGILD:CA
Gilead Sciences (GILD) provided updated 2026 guidance, projecting base business sales of $29.8B-$30.1B and raising its HIV growth outlook to 9%-10% from prior estimates. The upward revision is driven by strong performance across its HIV portfolio, Trodelvy, an…
- ▹Strong commercial execution with HIV portfolio growth and raised guidance, indicating robust demand.
- ▹Established company with multiple marketed products and manufacturing capabilities, but no major regulatory or technology catalysts in this news.
Watchlist · 77/100Aug 5, 2:43 AM EDT
Twist Bioscience Raises $300M in Upsized Public Offering
TWST
Twist Bioscience (TWST) has priced an upsized public offering of 3.125 million shares at $96 each, raising $300 million in gross proceeds. The capital raise provides the company with additional funding for its synthetic biology platform, which could support gr…
- ▹Upsized $300M equity offering provides strong cash runway, but dilutes existing shareholders.
- ▹Twist's synthetic biology platform is differentiated, but the company is still pre-commercial profitability.
Watchlist · 75/100Aug 4, 6:01 PM EDT
BioNTech Guides 2026 Revenue to €1.6B-€1.9B, Pivots to Late-Stage Oncology Catalysts
BNTX
BioNTech (BNTX) provided 2026 revenue guidance of €1.6B-€1.9B, signaling a shift toward its oncology pipeline as key catalysts approach late 2026. The company also confirmed Guido Oelkers will assume the CEO role by February 1, bringing commercialization exper…
- ▹Strong revenue guidance for 2026 indicates commercial traction, but oncology pipeline is still in late-stage development.
- ▹Leadership transition and multiple oncology catalysts provide positive narrative, but single-asset dependence and dilution risk cap upside.
Watchlist · 70/100Aug 5, 5:41 AM EDT
Ultragenyx Eyes Two Gene Therapy FDA Decisions by Fall 2026, Aims for Profitability in 2027
RARE
Ultragenyx (RARE) reported its strongest quarterly revenue ever in Q2 2026, reaffirming its full-year guidance. The company anticipates two gene therapy PDUFA dates in August and September 2026, and is targeting profitability by 2027, marking key catalysts for…
- ▹Two gene therapy PDUFAs in 2026 provide near-term regulatory catalysts, but no accelerated path or surrogate endpoint mentioned.
- ▹Strong commercial revenue growth and profitability target in 2027 support commercial viability, but single-asset focus and dilution risk cap upside.
Watchlist · 65/100Aug 5, 4:54 AM EDT
Gilead Maintains Quarterly Payout at $0.82 Per Share
GILD
Gilead Sciences (GILD) declared a quarterly dividend of $0.82 per share, consistent with its previous payout, representing a forward yield of 2.43%. The dividend is payable on Sept. 29 to shareholders of record as of Sept. 15, with the ex-dividend date also on…
- ▹Dividend declaration is routine, no regulatory impact; Gilead has no recent FDA negatives.
- ▹Large-cap with commercialized products, but news is purely financial, not a catalyst.
Watchlist · 65/100Aug 5, 1:31 AM EDT
Precigen Projects PAPZIMEOS Margins in High 80s–Low 90s, Aims for Cash Flow Breakeven by End of 2026
PGEN
Precigen (PGEN) reported Q2 PAPZIMEOS revenue of $53.1 million, up over 145% from Q1's $21.6 million, signaling a sharp launch acceleration. Management expects gross margins to stabilize in the high 80% to low 90% range and targets cash flow breakeven by end o…
- ▹PAPZIMEOS revenue growth strong (145% QoQ) with commercial traction and path to cash flow breakeven.
- ▹Single-asset company with no platform diversification, but differentiated gene therapy technology and US manufacturing.
Watchlist · 65/100Aug 4, 4:07 PM EDT
Twist Bioscience Announces $250M Common Stock Offering to Fund Growth
TWST
Twist Bioscience (TWST) has initiated an underwritten public offering of $250 million in common stock, with an option for underwriters to buy an additional $37.5 million in shares over 30 days. The proceeds are expected to support the company's growth initiati…
- ▹Dilutive offering raises capital but signals potential cash runway concerns.
- ▹Platform technology and synthetic biology capabilities remain differentiated.
Neutral · 62/100Aug 5, 2:21 AM EDT
Syndax Projects Revuforj U.S. Sales to Exceed $2B Peak as Key Axatilimab Data Looms
SNDX
Syndax Pharmaceuticals (SNDX) reported combined Q2 sales of $115 million for Revuforj and Niktimvo, with each drug annualizing above $200 million. Management now forecasts U.S. peak net revenue for Revuforj to surpass $2 billion, while investors await Q4 reado…
- ▹Revuforj and Niktimvo are commercialized and growing, with combined quarterly sales of $115M, indicating strong commercial traction.
- ▹Pipeline includes axatilimab with upcoming Q4 readouts, but company is still single-asset dependent for growth, limiting upside.
Neutral · 62/100Aug 5, 1:01 AM EDT
ACADIA Guides 2026 DAYBUE Sales to $480M-$510M; Key Alzheimer's Psychosis Data Expected This Fall
ACAD
ACADIA Pharmaceuticals (ACAD) reported Q2 2026 revenues of $308 million, driven by strong sales of DAYBUE and NUPLAZID. Management guided 2026 DAYBUE sales to $480M-$510M and anticipates Phase II data for remlifanserin in Alzheimer's disease psychosis in Septe…
- ▹DAYBUE and NUPLAZID commercial execution strong, with 2026 sales outlook of $480M-$510M for DAYBUE alone.
- ▹Remlifanserin Phase II data expected Sep-Oct, but single-asset pipeline and no regulatory clarity cap upside.
Neutral · 62/100Aug 4, 10:10 PM EDT
Rigel Guides 2026 Revenue to $285M-$295M Ahead of August VEPPANU Rollout
RIGL
Rigel Pharmaceuticals (RIGL) provided 2026 total revenue guidance of $285M-$295M, reflecting strong Q2 performance and the upcoming mid-August launch of VEPPANU. The company is positioning itself as a diversified oncology/hematology player, which could drive i…
- ▹Commercial launch of VEPPANU with revenue guidance indicates growth, but single-asset focus and lack of regulatory catalysts cap upside.
- ▹In-license of additional assets suggests pipeline expansion, but platform moat remains limited.
Neutral · 62/100Aug 4, 9:30 PM EDT
Travere's FILSPARI Surges Past Expectations, Pointing to $3B+ Peak Sales Potential
TVTX
Travere Therapeutics (TVTX) reported an exceptional Q2 2026, with FILSPARI now commercially available for both IgA nephropathy and FSGS. The drug's launch in FSGS has exceeded expectations, leading management to signal potential peak annual sales exceeding $3…
- ▹FILSPARI launch exceeding expectations in FSGS and IgA nephropathy, with potential $3B peak sales.
- ▹Single-asset company with limited pipeline diversification, but strong commercial momentum and regulatory approvals.
Neutral · 62/100Aug 4, 8:42 PM EDT
Arrowhead to File sNDA by End of 2026 After Phase III Success: 79-81% Triglyceride Reduction, 78% Fewer Pancreatitis Events
ARWR
Arrowhead Pharmaceuticals (ARWR) announced plans to submit a supplemental New Drug Application (sNDA) by the end of 2026, following positive Phase III results from the SHASTA-3 and SHASTA-4 trials. The therapy demonstrated 79-81% reductions in triglycerides an…
- ▹Positive Phase III results with strong efficacy and pancreatitis reduction, but sNDA not until end of 2026, limiting near-term regulatory upside.
- ▹Platform technology with multiple assets, but single lead asset and no recent BD/M&A cap technology score.
Neutral · 62/100Aug 4, 2:31 PM EDT
Exagen Hits Record Q2 Revenue, Guides to $72M-$75M for 2026 as Path to Profitability Clears
XGN
Exagen (XGN) reported record Q2 revenue of $19.9 million, up 16% year-over-year, driven by strong AVISE test volumes and higher ASPs. Management guided to $72M-$75M in 2026 revenue, signaling confidence in nearing breakeven profitability, a key milestone for i…
- ▹Record revenue growth and path to profitability, but single-asset focus and no major regulatory catalysts.
- ▹Diagnostics market with reimbursement support, but limited platform differentiation.
Neutral · 59/100Aug 4, 4:01 PM EDT
Rhythm Projects Japan IMCIVREE Approval by Late 2026, Sets 2026 OpEx Guidance at $363M-$397M
RYTM
Rhythm Pharmaceuticals (RYTM) announced it expects to receive approval for IMCIVREE in acquired hypothalamic obesity (HO) in Japan by the end of 2026, while updating its 2026 non-GAAP operating expense guidance to $363M-$397M. The company highlighted a strong…
- ▹IMCIVREE launch in acquired hypothalamic obesity shows commercial progress, but single-asset focus and long timeline to Japan approval cap upside.
- ▹OpEx guidance increase raises dilution risk, offsetting positive regulatory momentum.
Neutral · 58/100Aug 4, 1:38 PM EDT
Moderna Doses First Participants in Phase 1 Trial for Ebola Vaccine Candidate
MRNA
Moderna (MRNA) has initiated a Phase 1 trial in Canada for its mRNA-based Ebola vaccine (mRNA-1469), targeting the Bundibugyo ebolavirus. The study will enroll approximately 80 healthy adults, marking a key step in expanding Moderna's mRNA platform beyond COVI…
- ▹Phase 1 trial initiation for Ebola vaccine, but early stage and no accelerated path or regulatory clarity.
- ▹Moderna's mRNA platform is a strong technology, but this is a single-asset program with limited commercial potential.
Neutral · 50/100Aug 4, 3:51 PM EDT
Palvella Eyes FDA Filing and Commercial Launch, Projects $85M-$95M Cash Burn in 2026
PVLA
Palvella Therapeutics (PVLA) reported Q2 2026 milestones including positive Phase III SELVA results and FDA rolling review, positioning for a potential FDA approval in 1H 2027. The company plans to hire ~40 sales reps and expects $85M-$95M cash spend in 2026,…
- ▹Phase III success and rolling review support regulatory progress, but approval is far off (1H 2027).
- ▹Single-asset micro-cap with high cash burn and no commercial infrastructure yet.
High Risk · 40/100Aug 4, 10:58 AM EDT
Sagimet Biosciences Surges 8% as Volatility Continues
SGMT
Sagimet Biosciences (SGMT) saw its shares rise over 8% to $7.73, continuing a period of significant volatility. The clinical-stage biopharma, focused on fatty acid synthase inhibitors, has experienced sharp swings in recent weeks, which may be of interest to i…
- ▹Clinical-stage single-asset company with no regulatory clarity or recent catalysts.
- ▹Stock volatility and lack of commercial progress cap upside.
High Risk · 37/100Aug 4, 4:30 PM EDT
Dow and S&P 500 Hit Record Highs; Key Movers to Watch in After-Hours Trading
DJISP500
Wall Street's major indices closed sharply higher on Tuesday, with the Dow and S&P 500 both advancing 1.7% to new record highs. Investors should monitor after-hours trading for potential moves in stocks like SPCX, GILD, and AMD, which could impact portfolio pe…
- ▹No specific FDA or regulatory news; generic market update with no company-specific catalysts.
- ▹No platform or differentiated technology; single-asset micro-caps and large caps without relevant news.
High Risk · 32/100Aug 4, 12:49 PM EDT
Wall Street's Most Shorted Stocks Brace for Earnings-Driven Volatility
ITOWL
As earnings season ramps up, investors are monitoring heavily shorted stocks, defined as those with short interest exceeding 10% of float, for potential sharp price swings. Elevated short interest often signals bearish sentiment, but such stocks can also exper…
- ▹No specific FDA or regulatory catalysts mentioned; generic short interest news lacks substance.
- ▹No platform or differentiated technology; single-asset focus with no recent BD/M&A.